Based on the Rossari Biotech Limited stock forecast from 3 analysts, the average analyst target price for Rossari Biotech Limited is INR 868.00 over the next 12 months. Rossari Biotech Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Rossari Biotech Limited is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Rossari Biotech Limited’s stock price was INR 756.15. Rossari Biotech Limited’s stock price has changed by +2.66% over the past week, +10.17% over the past month and +10.15% over the last year.
No recent analyst target price found for Rossari Biotech Limited
No recent average analyst rating found for Rossari Biotech Limited
Company Overview Rossari Biotech Limited
Rossari Biotech Limited engages in manufacture and sale of specialty chemicals in India and internationally. It offers soap and detergents; inks, paints, and coatings; ceramics and tiles; pulp and papers; cement; performance additives; and water treatment solutions. The company also provides textile specialty chemicals, such as cotton, polyester, acrylic, wool, silk, nylon, functional finishes, denim, printing, and sustainable solutions; and pet grooming products, which include natural pet shampoos, powders, deodorants, sprays, creams, and floor washing liquids under the Lozalo, Hunger Fills, and Sniffy brand names. In addition, it provides poultry nutrition products comprising vitamin-mineral formulations, toxin binders, individual and cocktail enzymes, liquid nutraceuticals, and supplements or herbal preparations. The company was formerly known as Rossari Labtech and changed its name to Rossari Biotech Limited in December 2003. The company was founded in 1997 and is based in Mumbai, India. Read Less
Rossari Biotech Limited engages in manufacture and sale of specialty chemicals in India and internationally. It offers soap and detergents; inks, paints, and coatings; ceramics and tiles; pulp and papers; cement; performance additives; and water treatment solutions. The company a...Read More
Frequently Asked Questions About Rossari Biotech Limited (ROSSARI:NSE) Stock
Based on ratings from 3 analysts Rossari Biotech Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 4 buy, 1 sell and hold ratings.
ROSSARI:NSE stock's dividend yield is 0.07%.
Our analysis grades ROSSARI:NSE stock's dividend yield at F. This means that ROSSARI:NSE stock's dividend yield is above 4% of the stocks in the Specialty Chemicals sector in the NSE exchange.
Based on this ROSSARI:NSE may be a poor dividend stock for its sector.
Based on targets from 3 analysts, the average taret price for ROSSARI:NSE is INR 868.00 over the next 12 months. The maximum analyst target price is INR 926 while the minimum anlayst target price is INR 720.
ROSSARI:NSE stock's Price/Earning ratio is 31.94.
Our analysis grades ROSSARI:NSE stock's Price / Earning ratio at F. This means that ROSSARI:NSE stock's Price/Earning ratio is above 42.00000000000001% of the stocks in the Specialty Chemicals sector in the NSE exchange.
Based on this ROSSARI:NSE may be fairly valued for its sector
The last closing price of ROSSARI:NSE's stock was INR 756.15.
The most recent market capitalization for ROSSARI:NSE is INR 40.04B.
Based on targets from 3 analysts, the average taret price for ROSSARI:NSE is projected at INR 868.00 over the next 12 months.
This means that ROSSARI:NSE's stock price may go up by +14.79% over the next 12 months.
We can't find any ETFs which contains Rossari Biotech Limited's stock.
As per our most recent records Rossari Biotech Limited has 500 Employees.
Rossari Biotech Limited's registered address is 201 A & B, Akruti Corporate Park, Mumbai, India, 400078.
You can get more information about it from Rossari Biotech Limited's website at https://www.rossari.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ROSSARI:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
